Azetukalner

VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of October 1, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $38.93 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of October 1, 2026. The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee’s start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient’s continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan. The RSUs will vest as to 25% of the underlying shares on each of the first four anniversaries of the grant date of October 1, 2026, subject to such employee’s continued service relationship with the Company. Each RSU grant is subject to the terms and conditions of the restricted share unit award agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K V 7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K V 7 and Na V 1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit and follow us on LinkedIn and X . Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner. Contacts: For Investors: Laura Perry/Emily Huang Argot Partners Xenon@argotpartners.com For Media: Colleen Alabiso Senior Vice President, Corporate Affairs media@xenon-pharma.com

Toronto, Ontario--(News - September 29, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, as the recipient of the 2026 Bloom Burton Award. 2026 Bloom Burton Award Winner Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals To view an enhanced version of this graphic, please visit: In the past year, Ian Mortimer lead Xenon through an incredible period of performance, including unprecedented and positive phase 3 clinical trial results with Xenon's novel epilepsy treatment Azetukalner in adults with focal onset seizures, the filing of a new drug application with the U.S. FDA, and the execution of a US$747.5 million follow-on financing, which is the largest equity offering by a Canadian biotechnology company in history. "It was joyful to celebrate the phenomenal achievements of Ian Mortimer and the success of Xenon Pharmaceuticals in just the past year at the 2026 Bloom Burton Award Gala," said Jolyon Burton, President and Head of Investment Banking of Bloom Burton. "What a privilege to commemorate the achievements of all our finalists, and to acknowledge the growth and global contribution of our Canadian healthcare industry, positively impacting millions of people." Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada's innovative healthcare industry in the previous year. Nominations were accepted from any of the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services or digital health sectors, and equal consideration was given to contributions across any stage of development - from discovery to commercial-end markets. The Bloom Burton Award finalists and winner were chosen by an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism. This year's panel included: Michael Altman , Head of Strategy, Perceptive Advisors Christopher Arendt , Chief Scientific Officer, Head of Research, Takeda Karen Bernstein , Co-Founder and Chairman, BioCentury Joan Eliasek , President, North American Pharmaceutical Distribution, McKesson Carl Gordon , Managing Partner, OrbiMed Dennis Purcell , Founder and Senior Advisor, Aisling Capital Camille Samuels , Director, Venrock Boards All finalists - Ian Mortimer, Graham Rosenberg and Nate Tchaplia of Dentalcorp, and Ilia Tikhomirov formerly of 35Pharma - were celebrated at the black-tie 2026 Bloom Burton Award Gala held at The Ritz-Carlton, Toronto on September 24, 2026. Each finalist also received a $25,000 cash prize. For more information, please visit: . About Bloom Burton & Co. Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, strategic advisory, as well as company creation and incubation services. Bloom Burton Securities Inc. is a member of the Canadian Investment Regulatory Organization (CIRO) and is also a member of the Canadian Investor Protection Fund (CIPF). For additional information, please contact: Brian Bloom Chairman & CEO (416) 640-7575 bbloom@bloomburton.com To view the source version of this press release, please visit